Behbahani Ali has demonstrated a strong buying bias across their 38 reported transactions, with total purchases exceeding $20 million against just $260,518 in sales. The activity spans two primary companies: Black Diamond Therapeutics (BDTX) and Karooooo Ltd. (KRRO), with additional transactions involving Super Group (SGP) and NeueHealth (NEUE). Notably, on March 10, 2026, Ali executed two large acquisitions of KRRO stock worth approximately $2.7 million and $2.3 million, followed by a smaller $14,876 purchase of BDTX shares on March 20, 2026. Earlier in February 2026, Ali acquired $15 million in SGP securities through a private placement (code P), though most other SGP filings show derivative transactions with no reported value.
Prior activity includes mixed dealings with NEUE in October 2025, where Ali reported several small sales totaling about $22,647 alongside minor acquisitions and derivative adjustments. The pattern suggests a concentrated accumulation strategy, particularly in KRRO and SGP, with minimal divestment. The absence of officer or director titles in filings indicates these transactions may reflect personal investment decisions rather than corporate insider activity. The recent focus on KRRO and BDTX—both smaller-cap stocks—highlights Ali’s continued interest in these names, though the SGP private placement remains the single largest disclosed position.
AI-assisted summary